VivoSeq
Oncology

Lung Non-Small Cell Carcinoma

20

Pipeline Programs↗

13

Active Trials↗

12

Companies Involved↗

Lung Non-Small Cell Carcinoma is an emerging landscape with 20 programs across 12 companies. The most active players are Astellas, Regeneron, Gynecologic Oncology Group. 15 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

22/100

Mech. Concentration

24/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Astellas logo

Astellas

1 program

Phase 1Regeneron logo

Regeneron

1 program

Phase 2G

Gynecologic Oncology Group

3 programs

Phase 3AstraZeneca logo

AstraZeneca

2 programs

Phase 3A

Avyxa

2 programs

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

70%

Small molecule

14 of 20 classified programs — the dominant modality here.

30%ALL OTHERSMonoclonal antibody630%

Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 95% of 21 pipeline programs.

Analysis

Trial Status

14

clinical trials

Recruiting8 · 57%
Active, not recruiting4 · 29%
Completed1 · 7%
Not yet recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Recruiting·National Cancer Institute (NCI)·Phase 3·NCT04267848·1,210 enrolled
Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)
Recruiting·National Cancer Institute (NCI)·Phase 3·NCT07388524·336 enrolled
Geriatric Assessment and Management (GAM) for Older Adults With Non-Small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy (GAM-CRT)
Recruiting·CCity of Hope Medical Center·Preclinical·NCT06139627·180 enrolled
Involved-Station, Intensity-Modulated Post-Operative Radiation Therapy (I²-PORT) for Resected Non-Small Cell Lung Cancer With Residual Mediastinal Adenopathy After Neoadjuvant Therapy (ypN2)
Recruiting·Alliance for Clinical Trials in Oncology·Phase 2·NCT07293247·164 enrolled
Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants With Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in The AdjuvanT Setting (INSIGHT)
Recruiting·National Cancer Institute (NCI)·Phase 3·NCT06498635·306 enrolled
Perioperative Versus Adjuvant Systemic Therapy in Patients With Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG
Recruiting·Alliance for Clinical Trials in Oncology·Phase 3·NCT06632327·1,100 enrolled
Phase I Study of Gilteritinib for ALK Positive Non-Small Cell Lung Cancer
Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT06225427·30 enrolled
Boosting the Effects of Immunotherapy Through Exercise Training in Patients With Lung Cancer: The BOOST Trial
Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT06983899·100 enrolled
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Active, not recruiting·National Cancer Institute (NCI)·Preclinical·NCT02194738·8,300 enrolled
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT04310020·47 enrolled
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02595944·903 enrolled
A Randomized Phase III Trial of Checkpoint Blockade in Lung Cancer Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT06732401·630 enrolled
Phase II Trial: Photoimmunotherapy and Anti-PD1 in Patients With Refractory Inoperable and Metastatic Non-Small Cell Lung Cancer
Not yet recruiting·RRoswell Park Cancer Institute·Phase 2·NCT06943664·27 enrolled
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC)
Completed·National Cancer Institute (NCI)·Phase 3·NCT00324805·1,501 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)